Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

Operations

At Hikma, we’re proud of our extensive manufacturing and R&D capabilities.

Why?

Because we’re dedicated to creating high-quality medicines for millions of patients around the world.

This has been our focus for almost 50 years. We operate in 10 countries, 29 manufacturing plants, and 3 R&D hubs.

We make generic injectable medicines in these locations:

Dayton, New Jersey, US
Cherry Hill, New Jersey, US
Bedford, Ohio, US – coming soon
Goslar, Germany
Pavia, Italy
Terrugem, Portugal
Staoeuli, Algeria
Riyadh, KSA
Badr City, Egypt
Casablanca, Morocco – coming soon

Rx. Oral, respiratory and other generic medicines are produced here:

Columnus, Ohio, US

And branded generic medicines all over here:

Sidi Abdellah, Algeria
Staoueli, Algeria
Baba Ali, Algeria
Sidi Thabet, Tunisia
Casablanca, Morocco
Bayader, Jordan
Salt, Jordan
Sahab, Jordan
Riyadh, KSA
6TH October, Egypt
Beni Suef, Egypt

We’re committed to upholding the highest quality standards. 13 US FDA inspected plants, 12 EMA inspected plants.

By leveraging our footprint, we overcome obstacles of geography, supply and affordability, to put better health within reach, every day.

Core to Hikma’s strategy is having a strong local presence in our markets.

Manufacturing strength is one of our greatest assets and a key differentiator for us. We have 29 plants and 3 R&D hubs and continuously invest in expanding and enhancing our capabilities, strengthening our position as a local supplier with global expertise.

Top 10 generic pharma company in the US

We have three large manufacturing facilities in New Jersey and Ohio supply generic injectable, non-injectable and specialty products across a broad range of therapeutic areas, including respiratory, oncology and pain management. We also have a facility supplying compounded injectable products. We have two R&D facilities to support sustainable growth.

Largest pharma company in MENA

We sell branded generics and in-licensed patented products across the MENA. We have 20 manufacturing plants in six countries, including US FDA-inspected plants in Jordan and Saudi Arabia. Around 2,000 sales representatives and support staff market our brands to healthcare professionals across 18 markets. We also manufacture certain APIs through our API manufacturing facility in Jordan. Our significant footprint enables us to deliver on our corporate strategy and promote access to medicine across the region.

Growing presence in Europe

In Europe, we have manufacturing sites in Portugal, Germany and Italy, which supply our global markets with sterile injectable products. These facilities have a range of capabilities, including dedicated capacity for oncology, cephalosporins and lyophilised products. We have an R&D facility in Croatia, and commercial presence in Austria, BENELUX, France, Germany, Italy, Portugal, Spain and the UK.

Sterile injectable Oncology Lyophilisation Medicines
Key stats
9,500 employees
29 manufacturing plants
3 R&D hubs
13 US FDA-inspected plants
12 EMA-inspected plants
Related content

Explore more

1.  IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and the United Arab Emirates, MAT 2025
2. IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and the United Arab Emirates, MAT 2025